RMD

EX-99.1

2 d170451dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

For investors

For media

+1 858-221-3304

+1 619-510-1281

investorrelations@resmed.com

news@resmed.com

Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027

•

Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis

•

Q1 GAAP diluted earnings per share up 23% to $2.92; non-GAAP diluted EPS up 14% to $2.91

•

Returned more than $1.0 billion to shareholders through share repurchases and dividends during Q1

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, October 29, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended September 30, 2026.

“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business,” said Resmed’s Chairman and CEO, Mick Farrell. “Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%. Our strong free cash flow and the proceeds from our divestiture of MatrixCare enabled us to both invest in innovation and return more than $1 billion to shareholders during the quarter.”

“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”

Other Business and Operational Highlights

•

Closed the previously announced divestiture of the MatrixCare business.

•

Announced the U.S. launch of the AirTouch F40, the newest addition to Resmed’s growing portfolio of fabric CPAP masks.

•

Partnered with Eight Sleep to connect its technology with Resmed sleep insights for people in the U.S. and Australia, and with 23XI Racing NASCAR driver Tyler Reddick, following his sleep apnea diagnosis, to help others recognize the signs and seek treatment.

•

Announced appointment of Carol Burt as Lead Director, effective November 15, 2026, after the planned retirement of Director Ron Taylor.

RMD First Quarter 2027 Earnings Press Release – October 29, 2026

Page 2 of 13

Financial Results and Operating Metrics

(Unaudited; $ in millions, except for per share amounts)

Three Months Ended

September 30, 2026

September 30, 2025

% Change

Constant Currency (A)

Revenue

$ 1,415

$ 1,336

6 %

6 %

Gross margin (D)

61.5 %

61.2 %

30 bps

Non-GAAP gross margin (B)

62.5 %

62.0 %

50 bps

Research and development expenses (D)

103

89

15

13

Non-GAAP research and development expenses (B)

102

87

16

14

Selling, general, and administrative expenses (D)

315

282

12

11

Non-GAAP selling, general, and administrative expenses(B)

276

259

6

6

Income from operations

453

447

1

Operating margin

32.0 %

33.4 %

(140) bps

Non-GAAP income from operations (B)

506

482

5

Non-GAAP operating margin (B)

35.8 %

36.1 %

(30) bps

Net income

418

349

20

Non-GAAP net income (B)

418

375

12

Diluted earnings per share

$ 2.92

$ 2.37

23

Non-GAAP diluted earnings per share (B)

$ 2.91

$ 2.55

14

Operating cash flow

422

457

(8 )

Free cash flow (C)

374

414

(10 )

A.

In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP. Revenue growth on a core constant currency basis, which also excludes the impact of the Noctrix acquisition and the divestiture of the MatrixCare business, was 7%.

B.

See the reconciliation of non-GAAP financial measures in the table at

the end of the press release.

C.

Free cash flow is equal to operating cash flow less purchases of property, plant and equipment.

D.

During the first quarter of fiscal year 2027, we revised the presentation of restructuring expenses and amortization of acquired intangibles. Restructuring expenses, which were previously presented as a separate line item within operating expenses, are now classified within cost of sales, research and development expenses, and selling, general and administrative expenses based on the function of the associated costs. Amortization of acquired intangibles relating to cost of sales is